Kymera Therapeutics, Inc.

NASDAQ:KYMR

46.47 (USD) • At close November 1, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202320222021202020192018
Revenue 78.59246.82672.83234.0342.9340
Cost of Revenue 3.5652.9772.39762.1050.8250.205
Gross Profit 75.02743.84970.435-28.0712.109-0.205
Gross Profit Ratio 0.9550.9360.967-0.8250.7190
Reseach & Development Expenses 189.081164.248137.01762.10537.15817.679
General & Administrative Expenses 55.04143.83436.34518.2337.9813.772
Selling & Marketing Expenses 000000
SG&A 55.04143.83436.34518.2337.9813.772
Other Expenses 000000
Operating Expenses 244.122208.082173.36280.33845.13921.451
Operating Income -165.53-161.256-100.53-46.304-42.205-21.451
Operating Income Ratio -2.106-3.444-1.38-1.361-14.3850
Total Other Income Expenses Net 18.5686.4480.3130.7110.959-0.016
Income Before Tax -146.962-154.808-100.217-45.593-41.246-21.467
Income Before Tax Ratio -1.87-3.306-1.376-1.34-14.0580
Income Tax Expense 18.764-2.977-2.222-1.6480.0460.044
Net Income -146.962-151.831-97.995-43.945-41.292-21.467
Net Income Ratio -1.87-3.242-1.345-1.291-14.0740
EPS -2.52-2.82-2.04-2.53-0.93-1.07
EPS Diluted -2.52-2.82-2.04-2.53-0.93-1.07
EBITDA -143.201-154.632-100.042-45.478-40.375-21.246
EBITDA Ratio -1.822-3.302-1.374-1.336-13.7610